A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

NCT06041061 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18000

Last updated 2023-09-18

No results posted yet for this study

Summary

A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.

Conditions

Interventions

BIOLOGICAL

Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell)

According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine

BIOLOGICAL

placebo

According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo

Sponsors & Collaborators

  • Guangxi Center for Disease Control and Prevention

    collaborator OTHER_GOV
  • Henan Center for Disease Control and Prevention

    collaborator OTHER_GOV
  • Sichuan Center for Disease Control and Prevention

    collaborator OTHER_GOV
  • Centers for Disease Control and Prevention, China

    collaborator OTHER_GOV
  • Yunnan Center for Disease Control and Prevention

    collaborator OTHER
  • Sinocelltech Ltd.

    lead INDUSTRY

Principal Investigators

  • Yi Mo · Guangxi Center for Disease Control and Prevention

  • Yan Zheng · Yunnan Center for Disease Control and Prevention

  • Guohua Li · Centers for Disease Control and Prevention, China

  • Ting Huang · Sichuan Center for Disease Control and Prevention

  • Zhiqaing Xie · Henan Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-13
Primary Completion
2024-03-31
Completion
2028-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041061 on ClinicalTrials.gov